Age-related macular degeneration (AMD) is the leading cause of blindness in the US today, affecting approximately 10 million people. The dry or atrophic form accounts for 85-90% of cases and is characterized by slow decline of central vision function over many years. The wet or exudative form accounts for about 10% of cases and can lead to rapid and irreversible central vision loss. Since 2005, intraocular (intravitreal) therapy with injectable “anti-VEGF” drugs has revolutionized care of the wet form. New treatments for both forms of AMD are in development, with Colorado Retina taking part in over 30 promising clinical trials.